Education
About Us
Working with TipRanks
Follow Us
Otsuka Corporation (JP:4768)
:4768
Top Page
Otsuka
(OTC:4768)
63Neutral
Otsuka (4768) vs. S&P 500 (SPY)
Market Cap
¥1.18T
Dividend Yield2.41%
Average Volume (3M)898.61K
Price to Earnings (P/E)22.0
Beta (1Y)0.55
Revenue Growth13.33%
EPS Growth12.72%
CountryJP
Employees9,680
SectorTechnology
Sector Strength44
IndustryTechnology Distributors
Share Statistics
EPS (TTM)141.04
Shares Outstanding380,004,240
10 Day Avg. Volume958,330
30 Day Avg. Volume898,610
Financial Highlights & Ratios
PEG Ratio1.73
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,451.50Price Target Upside13.05% Upside
Rating ConsensusHold
Number of Analyst Covering4
Otsuka Business Overview & Revenue Model
Company DescriptionOtsuka Holdings Co., Ltd. (4768) is a diversified healthcare company based in Japan, operating primarily in the pharmaceuticals and nutraceuticals sectors. The company is known for its innovative approach to healthcare solutions, focusing on the research, development, manufacturing, and marketing of pharmaceuticals, including treatments for mental health and oncology, as well as a broad range of consumer products such as nutritional beverages and functional foods.
How the Company Makes MoneyOtsuka makes money through multiple revenue streams primarily derived from its pharmaceuticals and nutraceuticals divisions. In the pharmaceuticals sector, the company generates revenue by developing and selling prescription medications, with a strong emphasis on central nervous system disorders and oncology. Key products include antipsychotic medications and cancer treatments. The nutraceuticals division contributes to the company's earnings by offering health and wellness products, such as electrolyte drinks and nutritional supplements, directly to consumers. Otsuka also benefits from strategic partnerships and collaborations with other pharmaceutical companies and research institutions, expanding its market reach and leveraging shared resources for product development. The company invests significantly in research and development to maintain a robust pipeline of new products, ensuring long-term revenue growth.
Otsuka Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 1.11T | 977.37B | 861.02B | 851.89B | 836.32B | Gross Profit |
| 224.47B | 203.98B | 184.17B | 176.89B | 173.72B | EBIT |
| 74.36B | 62.96B | 54.77B | 55.83B | 56.31B | EBITDA |
| 82.65B | 72.86B | 63.06B | 63.81B | 63.92B | Net Income Common Stockholders |
| 53.48B | 47.45B | 40.02B | 39.93B | 39.31B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 228.14B | 228.69B | 202.29B | 204.70B | 178.07B | Total Assets |
| 673.90B | 561.80B | 523.02B | 486.25B | 471.29B | Total Debt |
| 6.86B | 7.30B | 7.51B | 7.99B | 8.02B | Net Debt |
| -221.28B | -221.39B | -194.78B | -196.72B | -170.05B | Total Liabilities |
| 298.66B | 214.85B | 200.29B | 184.48B | 191.26B | Stockholders Equity |
| 370.80B | 343.11B | 319.39B | 298.74B | 277.35B |
| Cash Flow | Free Cash Flow | |||
| 34.49B | 61.30B | 22.12B | 46.99B | 23.63B | Operating Cash Flow |
| 37.71B | 71.65B | 29.20B | 57.87B | 32.50B | Investing Cash Flow |
| -11.95B | -21.47B | -8.36B | -9.16B | -8.72B | Financing Cash Flow |
| -25.89B | -23.84B | -23.31B | -21.96B | -20.99B |
Otsuka Technical Analysis
Negative
3053.00
Price Trends
3296.87
Negative
3419.73
Negative
3383.42
Negative
Market Momentum
-73.03
Negative
40.00
Neutral
76.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4768, the sentiment is Negative. The current price of 3053 is below the 20-day moving average (MA) of 3122.73, below the 50-day MA of 3296.87, and below the 200-day MA of 3383.42, indicating a bearish trend. The MACD of -73.03 indicates Negative momentum. The RSI at 40.00 is Neutral, neither overbought nor oversold. The STOCH value of 76.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4768.
Otsuka Peers Comparison
Overall Rating
UnderperformOutperform
Sector (58)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
87 Outperform | $1.90T | 10.90 | 13.11% | 2.50% | 1.58% | 12.48% | |
79 Outperform | $10.34T | 26.70 | 21.61% | 1.17% | 5.33% | 18.98% | |
68 Neutral | $6.68T | 31.93 | 2.87% | 4.37% | 9.83% | 15.49% | |
65 Neutral | ¥1.14T | 19.52 | 6.83% | 3.75% | 5.63% | 30.61% | |
63 Neutral | ¥1.18T | 22.04 | 14.69% | 2.41% | 13.33% | 12.72% | |
62 Neutral | $2.29T | 49.09 | -3.80% | 5.53% | 21.01% | -12669.88% | |
58 Neutral | $9.99B | 10.12 | -6.46% | 3.10% | 7.47% | -11.60% |
* Technology Sector Average
Performance Comparison
JP:4768
Otsuka
3,108.00
26.49
0.86%
JP:4503
Astellas Pharma
1,349.50
-73.96
-5.20%
JP:4519
Chugai Pharmaceutical Co
8,313.00
3,164.58
61.47%
JP:4507
Shionogi & Co
2,399.00
13.36
0.56%
JP:4523
Eisai Co
4,038.00
-1,854.43
-31.47%
JP:4502
Takeda Pharmaceutical Co
4,300.00
359.59
9.13%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.